复发性静脉血栓形成的流行病学。
Epidemiology of recurrent venous thrombosis.
机构信息
Divisão de Hemostasia, Departamento de Hematologia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.
出版信息
Braz J Med Biol Res. 2012 Jan;45(1):1-7. doi: 10.1590/s0100-879x2011007500166. Epub 2011 Dec 23.
Abstract
Venous thrombosis, including deep vein thrombosis and pulmonary embolism, is a common disease that frequently recurs. Recurrence can be prevented by anticoagulants, but this comes at the risk of bleeding. Therefore, assessment of the risk of recurrence is important to balance the risks and benefits of anticoagulant treatment. This review briefly outlines what is currently known about the epidemiology of recurrent venous thrombosis, and focuses in more detail on potential new risk factors for venous recurrence. The general implications of these findings in patient management are discussed.
摘要
静脉血栓形成，包括深静脉血栓形成和肺栓塞，是一种常见的疾病，经常复发。抗凝剂可以预防复发，但这存在出血的风险。因此，评估复发风险对于平衡抗凝治疗的风险和益处非常重要。本综述简要概述了目前已知的复发性静脉血栓形成的流行病学情况，并更详细地介绍了静脉血栓复发的潜在新危险因素。讨论了这些发现对患者管理的一般影响。
相似文献
1
Epidemiology of recurrent venous thrombosis.
Braz J Med Biol Res. 2012 Jan;45(1):1-7. doi: 10.1590/s0100-879x2011007500166. Epub 2011 Dec 23.
2
Risk assessment for recurrent venous thrombosis.
Lancet. 2010 Dec 11;376(9757):2032-9. doi: 10.1016/S0140-6736(10)60962-2. Epub 2010 Dec 3.
3
Treatment of DVT: how long is enough and how do you predict recurrence.
J Thromb Thrombolysis. 2008 Feb;25(1):37-44. doi: 10.1007/s11239-007-0103-z. Epub 2007 Oct 1.
4
Duration of anticoagulation treatment in patients with venous thromboembolism.
J Am Osteopath Assoc. 2010 Nov;110(11):638-44.
5
Risk assessment and novel therapeutic approaches: reducing the incidence and recurrence of deep vein thrombosis in the surgical patient. Conclusion.
Orthopedics. 2000 Jun;23(6 Suppl):s655-6.
6
Deep vein thrombosis and pulmonary embolism.
Lancet. 2016 Dec 17;388(10063):3060-3073. doi: 10.1016/S0140-6736(16)30514-1. Epub 2016 Jun 30.
7
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Eur J Intern Med. 2014 Jan;25(1):25-30. doi: 10.1016/j.ejim.2013.09.005. Epub 2013 Oct 9.
8
Posttreatment ultrasound-detected residual venous thrombosis: a risk factor for recurrent venous thromboembolism and mortality.
Curr Opin Pulm Med. 2007 Sep;13(5):403-8. doi: 10.1097/MCP.0b013e32821642fb.
9
[Recurrence risk in venous thromboembolic disease after anticoagulation discontinuation].
Med Clin (Barc). 2013 Apr 15;140(7):310-3. doi: 10.1016/j.medcli.2012.06.023. Epub 2012 Sep 18.
10
Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study.
BMJ Open. 2020 Nov 3;10(11):e038102. doi: 10.1136/bmjopen-2020-038102.
引用本文的文献
1
Fibrinogen genotypes and their impact on recurrence of venous thromboembolism and family history: A prospective population-based study.
Br J Haematol. 2025 Feb;206(2):657-665. doi: 10.1111/bjh.19999. Epub 2025 Jan 19.
2
Joint Guideline on Venous Thromboembolism - 2022.
Arq Bras Cardiol. 2022 Apr;118(4):797-857. doi: 10.36660/abc.20220213.
3
Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study.
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029620979575. doi: 10.1177/1076029620979575.
4
Recurrent Deep Vein Thrombosis After the First Venous Thromboembolism Event: A Single-Institution Experience.
Med Sci Monit. 2017 May 20;23:2391-2399. doi: 10.12659/msm.901924.
5
Von Willebrand factor is reversibly decreased during torpor in 13-lined ground squirrels.
J Comp Physiol B. 2016 Jan;186(1):131-9. doi: 10.1007/s00360-015-0941-5.
6
Clinical update on pulmonary embolism.
Arch Med Sci. 2014 Jun 29;10(3):557-65. doi: 10.5114/aoms.2013.34325. Epub 2013 May 7.
本文引用的文献
1
Past provoking venous thrombosis risk situations on the risk of a recurrent thrombotic event: a cohort study.
Thromb Res. 2011 Sep;128(3):227-32. doi: 10.1016/j.thromres.2011.04.015. Epub 2011 May 19.
2
Residual venous thrombosis as predictive factor for recurrent venous thromboembolim in patients with proximal deep vein thrombosis: a sytematic review.
Br J Haematol. 2011 Apr;153(2):168-78. doi: 10.1111/j.1365-2141.2011.08578.x. Epub 2011 Mar 6.
3
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis.
BMJ. 2011 Feb 24;342:d813. doi: 10.1136/bmj.d813.
4
Extended anticoagulation for unprovoked venous thromboembolism: a majority of patients should be treated.
J Thromb Thrombolysis. 2011 Apr;31(3):295-300. doi: 10.1007/s11239-011-0573-x.
5
Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies.
Blood Coagul Fibrinolysis. 2011 Mar;22(2):86-91. doi: 10.1097/MBC.0b013e328341f030.
6
Risk assessment for recurrent venous thrombosis.
Lancet. 2010 Dec 11;376(9757):2032-9. doi: 10.1016/S0140-6736(10)60962-2. Epub 2010 Dec 3.
7
Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event.
J Thromb Haemost. 2010 Oct;8(10):2159-68. doi: 10.1111/j.1538-7836.2010.03994.x.
8
Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis.
J Thromb Haemost. 2010 Nov;8(11):2436-42. doi: 10.1111/j.1538-7836.2010.04022.x.
9
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management.
Ann Oncol. 2010 May;21 Suppl 5:v274-6. doi: 10.1093/annonc/mdq199.
10
Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension.
J Thromb Haemost. 2010 Sep;8(9):1933-42. doi: 10.1111/j.1538-7836.2010.03955.x.
Zotero 插件